FDA staff urges new caution on Roche flu drug
13th Nov 2006, 19:14 GMT
WASHINGTON (Reuters) - U.S. Food and Drug Administration staff have recommended adding a new precaution to the label of Roche AG's flu-fighting drug Tamiflu about reports of psychiatric problems in patients who take it, according to documents made public on Monday.
FDA staff urges new caution on Roche flu drug related news:
- FDA staff urges new caution on Roche flu drug — Monsters and Critics News
- FDA staff urges new caution on Roche flu drug (Reuters) — Yahoo! News: Top Stories
- FDA Urges Caution on Flu Drug — WSJ.com: What's News US
- Roche flu drug to carry new caution in U.S. — Reuters: Health
- FDA Orders Caution Over the use of Tamiflu — NPR Topics: Nation
- FDA Suggests New Tamiflu Warning — WSJ.com: What's News US
- Flu Drug Label Will Warn of Risks, FDA Says — washingtonpost.com - A Section
- FDA urges monitoring of Tamiflu patients — Boston Globe -- National News
- Tamiflu label gets 'abnormal behavior' warning — baltimoresun.com - nation/world
- FDA Posts New Tamiflu Warning — WebMD Health Headlines
Latest news from Reuters: Health:
- Camel milk ice cream to help trim Indian waists
- Diseased gums raise risk of pancreatic cancer
- Simple steps can speed heart attack care: study
- Children showing hardening of arteries: U.S. study
- Antibodies destroy HIV-infected cells
- New drug comb may lengthen ovarian cancer survival
- FDA OKs Genentech drug for early breast cancer
- Drug switch improves breast cancer survival: study